Sugi Predict

Sugi Predict / Compounds / SCHEMBL132798

SCHEMBL132798

SCHEMBL132798

[CH2]Cc1ccccc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 0.57
▸ TAAR1 Q96RJ0 1/20 0.57
▸ CHRM2 P08172 4/20 0.55
▸ CHRM1 P11229 1/20 0.55
▸ CA1 P00915 2/20 0.55
▸ CA2 P00918 2/20 0.55
▸ CA7 P43166 2/20 0.55
▸ CA9 Q16790 2/20 0.55
▸ CA12 O43570 1/20 0.55
▸ CA4 P22748 1/20 0.55
▸ CA14 Q9ULX7 1/20 0.55
▸ ALDH1A1 P00352 2/20 0.53
▸ GAA P10253 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ SIGMAR1 Q99720 1/20 0.50
▸ AOC3 Q16853 1/20 0.50
▸ GRIN1 Q05586 3/20 0.48
▸ GRIN2A Q12879 3/20 0.48
▸ BCHE P06276 2/20 0.48
▸ ACHE P22303 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL840064 0.82 TAAR1 (0.64) IDO1TAAR1CHRM2CHRM1CA1
SCHEMBL1145669 0.81 IDO1 (0.57) IDO1TAAR1CHRM2CHRM1CA1
SCHEMBL10607688 0.81 IDO1 (0.69) IDO1TAAR1CHRM2CHRM1CA1
SCHEMBL1547806 0.80 SMN1; SMN2 (0.50) CA1CA2CA12CA14ALDH1A1
SCHEMBL3296809 0.80 IDO1 (0.61) IDO1TAAR1CHRM2CHRM1CA1
SCHEMBL28858018 0.80 TAAR1 (0.75) IDO1TAAR1CHRM2CHRM1CA1
SCHEMBL399492 0.79 TAAR1 (0.60) IDO1TAAR1CHRM2CHRM1CA1
SCHEMBL17187879 0.79 CYP2C9 (0.47) IDO1TAAR1CHRM2CHRM1CA1
SCHEMBL3166142 0.79 IDO1 (0.60) IDO1TAAR1CHRM2CHRM1CA1
SCHEMBL17351757 0.79 IDO1 (0.46) IDO1TAAR1CHRM2CHRM1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2023-11-02 — — US claimed
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 — — US claimed
US-20230278958-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2023-09-07 — — US claimed
CN-116367565-A Quasi two-dimensional perovskite nanocrystalline modified three-dimensional perovskite solar cell 河北工业大学 2023-06-30 — — CN claimed
CN-111278797-B Fluorine-containing ether compound, lubricant for magnetic recording medium, and magnetic recording medium 株式会社力森诺科 2023-06-16 — — CN claimed
US-20230174538-A1 Tricyclic heterocycles MERCK PATENT GMBH (DE) 2023-06-08 — — US claimed
US-20230174486-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2023-06-08 — — US claimed
EP-4185564-A1 TRICYCLIC HETEROCYCLES Merck Patent GmbH (DE) 2023-05-31 — — EP claimed
CN-116134016-A Tricyclic heterocycles 默克专利股份公司 2023-05-16 — — CN claimed
WO-2023078813-A1 HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS MERCK PATENT GMBH (DE) 2023-05-11 — — WO claimed
EP-0174811-A2 7-(2-aminoethyl)-1,3-Benzthia- or oxa- zol-2(3H) -ones SMITHKLINE BECKMAN CORPORATION (US) 1986-03-19 — — EP claimed
EP-0167288-A2 4-(2-(N,N-disubstituted-amino)ethyl]isatins SMITHKLINE BEECHAM CORPORATION (US) 1986-01-08 — — EP claimed
US-4554287-A Antihypertensive 7-[2-(dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones SMITHKLINE BECKMAN CORPORATION (US) 1985-11-19 — — US claimed
US-4544652-A α-Hydroxyethylphosphinates, and their use as fungicides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1985-10-01 — — US claimed
US-4435392-A 2,5-Benzodiazocine derivatives and salts thereof, as well as pharmaceutical agent comprising as effective component at least one of the derivatives and salts SANWA KAGAKU KENKYUSHO CO. LTD. (JP) 1984-03-06 — — US claimed
EP-0093010-A2 Alpha-hydroxyethylphosphinates, and their production and use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1983-11-02 — — EP claimed
EP-0089743-A1 Novel 2,5-benzodiazocines and salts thereof having pharmaceutical activity SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1983-09-28 — — EP claimed
US-4379788-A HYPOTENSIVES, ANTIARRHYTHMIA, B-BLOCKERS DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1983-04-12 — — US claimed
US-4201864-A CHEMICAL INTERMEDIATES, PROSTAGLANDINS BEECHAM GROUP LIMITED (GB) 1980-05-06 — — US claimed
US-4016263-A BACTERICIDES BOEHRINGER INGELHEIM GMBH (DT) 1977-04-05 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS CSNK1A1, CSNK1D, CSNK1G1 IDO1 371/4885TAAR1 2732/4885CHRM2 1654/4885
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA IDO1 2392/4885TAAR1 4166/4885CHRM2 4763/4885
US-20230278958-A1 TRICYCLIC HETEROCYCLES YAP1, TERF2IP, TEAD1 IDO1 3982/4885TAAR1 3949/4885CHRM2 4830/4885
US-20230174486-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA IDO1 2392/4885TAAR1 4166/4885CHRM2 4763/4885
US-20230174538-A1 Tricyclic heterocycles YAP1, TEAD1, TERF2IP IDO1 3847/4885TAAR1 3665/4885CHRM2 4856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.